Fig. 6: WWOX loss in human PDAC patients and PDX models. | Cell Death & Disease

Fig. 6: WWOX loss in human PDAC patients and PDX models.

From: Loss of tumor suppressor WWOX accelerates pancreatic cancer development through promotion of TGFβ/BMP2 signaling

Fig. 6

A Low expression of WWOX correlates with worse overall survival of PDAC patients as assessed using KM plotter dataset. The red line indicates high expression, while the black line low expression of WWOX. B Immunoblotting of WWOX in PDXs and PDXs-WWOX overexpression. C Quantification of WWOX expression from B. D Quantification of colony formation of PDX-139, EV, and WWOX O.E, respectively. E Average tumor size of PDX-139 WT (n = 4), PDX-139 EV (n = 5), and PDX-139 WWOX O.E (n = 6). F Average tumor weight of PDX-139 WT (n = 4), PDX-139 EV (n = 5), and PDX-139 WWOX O.E (n = 6). G Immunoblotting of WWOX in PDX114, KO, and KO rescue. H Quantification of colony formation of PDX114, EV, KO, and KO rescue. NS > 0.05, *P < 0.05, **P < 0. 001, ***P < 0. 0001. Two-tail unpaired t-test. Quantification graphs are presenting the means ± SD.

Back to article page